

Supporting Information (SI) for:

**Highly modular hepatitis B virus-like nanocarriers for
therapeutic protein encapsulation and targeted delivery to
triple negative breast cancer cells**

Daniel Yur, Millicent O. Sullivan, and Wilfred Chen**

Department of Chemical and Biomolecular Engineering, University of Delaware, 150 Academy Street, Newark, DE 19716 United States of America

Corresponding authors: Millicent O. Sullivan email: msullivan@udel.edu and Wilfred Chen email: wilfred@udel.edu




Figure S1: Histogram of HBV_{SpyTag} particle sizes. Measurements of particle sizes from TEM images via Image J were taken of HBV_{SpyTag} from (A) pooled sucrose gradient ultracentrifugation fractions 7-10 and (B) ELP[KV8F-40]-SpyCatcher (ELP₄₀-SpyCatcher) purification samples. Error in average particle diameter is the standard deviation of the respective measured diameters.




Figure S2: Analysis of HBV-p19 protein self-assembly. **(A)** HBV-p19 was expressed in BL21 and the soluble and insoluble lysates were assessed with SDS-PAGE. Arrow shows the location of the HBV-p19. **(B)** Sucrose gradient ultracentrifugation separated HBV-p19 proteins that formed capsid-sized nanostructures (fractions 7-10) from proteins that were not assembled (fractions 1-6) and proteins that formed larger aggregates (fractions 11-14). Arrow shows the HBV-p19 protein across the different fractions. **(C)** TEM demonstrated the protein structures that were formed with pooled fractions (8 and 9) from the sucrose gradient analysis.




Figure S3: ELP₄₀-SpyCatcher reaction with HBV_{SpyTag}(GFP) lysates and subsequent inverse transition cycling. SDS-PAGE analysis was performed to assess the ligation of ELP₄₀ purification tags to HBV_{SpyTag} VLPs with 0% (A), 10% (B), or 25% (C) GFP loading and their subsequent purification through ITC: (1) ELP-SpyCatcher mixed with HBV_{SpyTag}(GFP) lysate at a 2:1 molar ratio, (2) Protein sample after overnight reaction, (3) Insoluble proteins post-reaction, (4) Soluble proteins post-reaction, (5) ITC: soluble contaminants, (6) ITC: Insoluble contaminants, (7) ITC: purified VLPs. The percentages are the average per VLP.




Figure S4: Purification of tri-expressed VLPs: HBV_{SpyTag}(GFP,yCD₂) (A) ELP₄₀-SpyCatcher reaction with tri-expressed HBV_{SpyTag}(GFP,yCD₂) VLPs and subsequent cycle of ITC: (1) ELP-SpyCatcher mixed with HBV_{SpyTag}(GFP,yCD₂) respective sample at a 2:1 molar ratio, (2) Post-reaction protein sample, (3) ITC: soluble contaminants, (4) ITC: Insoluble contaminants, (5) ITC: purified VLPs. Arrows point to labeled corresponding protein species. The percentages are the average per VLP. (B) Purified HBV_{SpyTag}(GFP,yCD₂) remained intact as confirmed by TEM.




Figure S5: Assessing how ligation density of ELPs on exterior of HBV_{SpyTag}(GFP) VLPs affect non-specific uptake in SUM149 cells. **(A)** SDS-PAGE demonstrated modification of HBV_{SpyTag}(GFP) the exterior of the VLP with a 15%, 25% or 40% ligation density of ELP[AV-60]-SpyCatcher (ELP₆₀-SpyCatcher). **(B)** Mean fluorescence intensity of HBV_{SpyTag}(GFP) modified with 5-40% ELP₆₀-SpyCatcher was delivered to SUM149 cells and assessed by flow cytometry. The percentages are the average per VLP.




Figure S6: Assembly of targeted HBV_{SpyTag}(GFP) and HBV_{SpyTag}(GFP,yCD₂) for cell-specific delivery. SDS-PAGE demonstrated modification of dual-expressed HBV_{SpyTag}(GFP) (**A**) and tri-expressed HBV_{SpyTag}(GFP,yCD₂) VLPs (**B**) with a total 40% ligation density of ELP₆₀-SpyCatcher, with targeted VLPs having a 10% density of DARPin_{EGFR} added at the N-terminus of 25% of the ligated ELP₆₀-SpyCatcher proteins. The percentages are the average per VLP.




Figure S7: Alternative tri-expression system for high yCD₂ loading in VLP. **(A)** The original tri-expression system was altered by switching the *E. coli* promoter controlling the HBV_{SpyTag}-yCD₂ and HBV_{SpyTag}-GFP genes. **(B)** SDS-PAGE analysis of soluble and insoluble lysates resulting from inducing expression with IPTG and arabinose or aTc, IPTG, and arabinose using the modified tri-expression system. Estimated mole percent of protein cargoes was assessed by using densitometry. Boxed protein band on SDS-PAGE corresponds to HBV-GFP protein. The percentages are the average per VLP. **(C)** Fluorescence of the soluble lysate samples with or without aTc was measured to confirm GFP production (Ex: 470 nm, Em: 520 nm). Error bars are standard deviation from technical replicates (N = 3).

Section 2: Supplementary Information

Tables S1: DNA primers used in restriction enzyme cloning

Name:	Sequence:
KpNI-GGGS GGG-SpyTag-GG-BamHI(+)	CGGAGGGGGAAGCGGTGGAGGTGCACAC ATAGTAATGGTAGACGCCTACAAGCCGAC GAAGGGTGGAG
KpNI-GGGS GGG-SpyTag-GG-BamHI(-)	GATCCTCCACCTTCGTCGGCTTGTAGGCG TCTACCATTACTATGTGTGCACCTCCACCG CTTCCCCCTCCGGTAC
NcoI-DARPin_EGFR_Fw	GATGATCCATGGATCTGGGCAAAAATTG TTAGAAG
NdeI-S-(G ₄ S) ₂ -GGSA-DARPin_EGFR_Rev	GATGATCATATGGCTTCCACCACCTCCTG AGCCGCCACCACCAGAGCCGCCGCTAGC ATTCAGTTTCTGCAGAATTTCCG
SacI-HBV _{SpyTag} _Fw	GATGATGAGCTCGATCCGGCTGCTAAC
XhoI-HBV _{SpyTag} _Rev	GATGATCTCGAGCCAACAACAGTAGTCTC CGGAAGTGTTG
XhoI-A-(G ₃ S) ₃ -G ₄ T-AgeI (+)	TCGAGTGCAGGTGGCGGTAGTGGTGGCGG GTCTGGAGGTGGCTCAGGCGGTGGAGGGA CTA
XhoI-A-(G ₃ S) ₃ -G ₄ T-AgeI (-)	CCGGTAGTCCCTCCACCGCCTGAGCCACC TCCAGACCCGCCACCACTACCGCCACCTG CAC
XhoI-GFP_Fw	GATGATACCGGTATGGTGAGCAAGGGCG
SacI-His6-GFP_Rev	GATGATGAGCTCTTAGTGATGGTGATGGT GATGCTTGACAGCTCGTCCATG
AgeI-yCD_Fw	GATGATACCGGTGTGACCGGCGGAATG
BamHI-G ₃ -yCD_Rev	GATGATGGATCCACCGCCACCTTCTCCAA TATCCTCAAACCAGTC
BamHI-G ₄ S-yCD_Fw	GATGATGGATCCGGTGGCGGGGGTTCCGGT GACCGGCGGAATG

AvrII-His6-yCD_Rev	GATGATCCTAGGTTAGTGATGGTGATGGT GATGTTCTCCAATATCCTCAAACCAGTC
SphI-HBV _{SpyTag} -GFP-h6 Fw	GATGATGCATGCATGGACATCGACCCTTA TAAAG
HBV _{SpyTag} -GFP-h6-AvrII Rev	GATGATCCTAGGTCATTAATGGTGATGGT GGTGATGCTTGACAGCTC

Tables S2: DNA primers used in Gibson assembly cloning

Name:	Sequence:
pET24a-HBV _{SpyTag} vector_Fw	GGGTCCTCAACGACAGGAG
pET24a-HBV _{SpyTag} vector_Rev	CTGGTTAGCAGAATGAATCACCGATAC
araC-pBad promoter_Fw	ATCGGTGATTCATTCTGCTAACCAGTAA GGCAGTTATTGGTGCCC
araC-pBad promoter_Rev	CAAATTCTTTATAAGGGTCGATGTCCAT GACTAGTCTCCTTCTTAAAGTTAAAC
HBV _{SpyTag} -GFP_Fw	GACATCGACCCTTATAAAGAATTTGGAG
HBV _{SpyTag} -GFP_Rev	AACAGATCTGATATCGGCGCTGGCGCCT AGGGCTTTGTTAGCAGCCGGATC
rrn1-rrn2 term_Fw	CGCCAGCGCCGATATC
rrn1-rrn2 term_Rev	ATCGTGCTCCTGTCGTTGAGGACCCAAG CTTAAGCTTGCGTTCTTCG